The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC CLL 2026 | Richter’s transformation in 2026: where does the field stand and what challenges remain?
Erin Parry, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the current state of Richter’s transformation and highlights significant scientific progress in understanding the disease’s biology, including dysregulated pathways. Dr Parry notes that the key challenge now is translating this knowledge into better patient outcomes, with promising new treatments on the horizon, including bispecific antibodies and novel combinations of targeted inhibitors. This interview took place at the 2026 ERIC International Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
